circled in red pen — read the caveats first
Tesamorelin Side Effects in the Research Literature
Injection-site reactions, growth-hormone-class effects, the IGF-1 growth-factor warning, the LiverTox safety read, and the labeled contraindications — marked plainly.
The short version
This page summarizes tesamorelin side effects as the studies and the FDA label report them. Most reported effects are mild: reactions at the injection site, and the kinds of effects growth hormone tends to cause — some fluid retention, joint aches, and modest shifts in blood sugar. Because tesamorelin raises IGF-1 (a growth signal), the label warns against use with active cancer, in pregnancy, and in anyone allergic to it. A drug-safety monograph rates it unlikely to harm the liver. None of this is medical advice, and research-grade material is not for human use.
What are the side effects of tesamorelin?
Reported effects center on injection-site reactions and growth-hormone-class effects — fluid balance, arthralgia (joint pain), and modest glucose perturbation — plus elevated IGF-1 [15]. The NIH LiverTox monograph assigns a likelihood score of E (unlikely cause of liver injury) [6]; active malignancy, hypersensitivity, and pregnancy are contraindications on the FDA label [15].
Growth-Hormone-Class Effects and IGF-1 Elevation
Because tesamorelin works by stimulating the body's own growth hormone, its side-effect profile tracks the growth-hormone class. The FDA prescribing label carries explicit warnings about stimulating endogenous growth hormone and raising serum IGF-1, the growth factor that mediates many downstream effects [15]. Reviews list peripheral oedema (fluid retention) and arthralgia among growth-hormone-associated events, with severity in trials generally mild.
IGF-1 elevation is consistent and substantial: +81.0% in the pivotal HIV trial [3], +181 ug/L in healthy men [7], and +117% in the cognition trial [8]. That elevation is the basis for the compound's growth-factor warnings and for the malignancy contraindication. It is also the marker investigators track to confirm the drug is doing what it is meant to do — a benefit and a caution carried by the same number.
Does tesamorelin cause water retention?
Fluid retention is a recognized growth-hormone-class effect, reflecting growth-hormone/IGF-1 axis stimulation; the FDA label carries warnings about stimulating endogenous growth hormone and raising serum IGF-1 [15], and reviews list peripheral oedema and arthralgia among growth-hormone-associated events. Severity in trials was generally mild.
IGF-1 Elevation and Malignancy: What Trials Showed
Tesamorelin raises IGF-1, a growth factor, which is why malignancy is the safety question that recurs. Over the 52-week pivotal program, trials showed no excess malignancy signal [4]; however, long-term oncologic-safety data are limited, and any preexisting active malignancy is a labeled contraindication — treatment must be complete and the malignancy inactive before use [15]. The honest read is that the medium-term trial record is reassuring and the long-term record is thin, which is exactly why the label draws a hard line around active cancer.
Does tesamorelin increase the risk of diabetes or affect blood sugar?
In 13 healthy men, two weeks of tesamorelin left fasting glucose (P=0.93) and insulin-stimulated glucose uptake (P=0.61) unchanged [7], and the 52-week HIV program reported no clinically significant glucose changes [4]. Modest glucose perturbation can occur as a growth-hormone-class effect, so monitoring is warranted in prediabetes or dysglycemia.
Glucose, Fluid Balance, and the Monitoring Question
Growth-hormone stimulation can nudge glucose handling, so blood-sugar effects are the metabolic signal worth watching. The reassuring data: in 13 healthy men, two weeks of tesamorelin left fasting glucose (P=0.93) and insulin-stimulated glucose uptake (P=0.61) unchanged [7], and across the 52-week HIV program changes in glucose parameters were not clinically significant [4]. A dedicated type-2-diabetes safety trial likewise found no significant HbA1c change. Even so, because modest glucose perturbation can occur as a growth-hormone-class effect, monitoring is warranted in individuals with prediabetes or dysglycemia. Fluid retention and arthralgia round out the growth-hormone-class profile, generally mild in the trials [15].
Who should not take tesamorelin / who should avoid it?
The FDA label contraindicates use in active malignancy (treatment must be complete and the malignancy inactive), known hypersensitivity to tesamorelin or excipients, and pregnancy — animal organogenesis studies showed hydrocephaly in offspring [15]. Research-grade material is not for human self-administration.
Contraindications and the LiverTox Read
The labeled contraindications are specific. The FDA prescribing label contraindicates tesamorelin in any preexisting active malignancy (treatment must be complete and the malignancy inactive before use), in known hypersensitivity to tesamorelin or its excipients, and in pregnancy — animal organogenesis studies showed hydrocephaly (fluid accumulation in the brain) in offspring [15]. These are circled in red here because they are the caveats a reader should not skim past.
On the liver, the record is comparatively clean. The NIH LiverTox monograph — the standard reference on drug-induced liver injury — assigns tesamorelin a likelihood score of E, meaning an unlikely cause of clinically apparent liver injury, noting no reported attributable liver-injury cases and no de novo serum-enzyme elevations in trials [6]. Tesamorelin is also prohibited in sport under WADA category S2. And the standing reminder: the lab-grade material discussed on this site is supplied for research, not for human self-administration, and lacks the purity and potency oversight of the approved product.